Article Information
History
- April 6, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Szu-Min Hsieh, M.D.1,
- Wang-Da Liu, M.D.1,
- Yu-Shan Huang, M.D.1,
- Yi-Jiun Lin, Ph.D.2,
- Erh-Fang Hsieh, Ph.D.2,
- Wei-Cheng Lian, Ph. D.2,
- Charles Chen, Ad. Prof.2,3,
- I-Chen Tai, M.D.2,* and
- Shan-Chwen Chang, M.D., Ph.D.1,*
- 1Section of Infectious Diseases, Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taiwan
- 2Medigen Vaccine Biologics Corp., Taiwan
- 3College of Science and Technology, Temple University, Philadelphia, PA 19122, U.S.A.
- ↵*Corresponding authors I-Chen Tai, Corresponding Author, Email: kathytai{at}medigenvac.com, Postal address: Medigen Vaccine Biologics Corp., 7F., No. 16, Ln. 120, Sec. 1, Neihu Rd., Taipei 114, Taiwan, TEL: +886-2-77450830 #604, Shan-Chwen Chang, Corresponding Author, Email: changsc{at}ntu.edu.tw, Postal address: National Taiwan University Hospital, No.7, Zhongshan S. Rd., Zhongzheng Dist., Taipei City 100, Taiwan, TEL: +886-2-23123456#887999
Posted April 06, 2021.
First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018
